BioTech/Drugs - Boston, MA, us
Raqia Therapeutics is an exciting startup company developing a transformative chimeric antigen receptor (CAR) technology for immunotherapy. Raqia launched in the Pagliuca Harvard Life Lab incubator after a competitive selection process and with a seed round of investment of $3M from top-tier billionaire investors with additional investment commitments expected in the next two quarters. Raqia has negotiated exclusive rights to a next-generation CAR T cell platform developed in the laboratory of Dr. Carl Novina at the Dana-Farber Cancer Institute. The company has assembled an impressive team of successful scientific and business advisors, including Drs. Nikhil Munshi, Ken Anderson on the SAB and Dr. Fred Mermelstein, successful scientist and biotech entrepreneur, as CEO.
Squarespace ECommerce
Gmail
NSOne
Typekit
Shutterstock